我要投票 朗迪Reneed在补钙行业中的票数:690
· 外 推 电 报 ·
2025-11-22 19:34:13 星期六

【朗迪Reneed是哪个国家的品牌?】

朗迪Reneed是什么牌子?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!将品牌入驻外推网,定制朗迪Reneed品牌推广信息,可以显著提高朗迪Reneed产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


英文翻译:Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://www.waitui.com/brand/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

澳大利亚将禁止机舱内使用充电宝

澳大利亚几家主要航空公司21日宣布,将于下月开始陆续禁止在航班上使用充电宝或为充电宝充电,以降低机舱内火灾风险。这些安全措施将适用于所有国内和国际航班,且不会给予任何豁免。据澳大利亚广播公司21日报道,澳洲航空公司及其旗下的澳航支线、捷星航空宣布将于12月15日起实施禁令,而维珍澳大利亚航空公司的禁令将从12月1日起执行。(财联社)

2小时前

峰飞航空:累计获得eVTOL确认订单300架

11月22日消息,峰飞航空累计获得eVTOL商业订单2000架,其中,截至2025年底的确认订单是300架。(证券时报)

2小时前

兆威机电、迈威生物港股IPO获中国证监会备案

11月22日消息,中国证监会国际合作司发布关于深圳市兆威机电股份有限公司、迈威(上海)生物科技股份有限公司境外发行上市备案通知书,兆威机电拟发行不超过69,058,450股境外上市普通股并在香港联合交易所上市。迈威生物拟发行不超过62,664,600股境外上市普通股并在香港联合交易所上市。(金十数据APP)

2小时前

阿斯利康宣布投资20亿美元扩建马里兰州生产基地

当地时间11月21日,阿斯利康宣布计划投资20亿美元,用于扩建其位于马里兰州的长期生产基地。此项投资将为该州创造2600个就业岗位,包括保留当地现有职位、建筑活动相关岗位,以及新增300个高技能职位。(界面新闻)

2小时前

我国卫星物联网业务商用试验正式启动

11月22日,在2025中国“5G+”工业互联网大会上,工业和信息化部对外宣布,我国卫星物联网业务商用试验正式启动。此次商用试验期为两年。目标通过开展商用试验,丰富卫星通信市场供给,激发市场主体活力,提升行业服务能力,建立安全监管体系,形成可复制可推广的经验和模式,支撑商业航天、低空经济等新兴产业安全健康发展,服务构建新发展格局。(第一财经)

2小时前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询